• Dimitrios Giannis, Ioannis A Ziogas, and Panagiota Gianni.
• Institute of Health Innovations and Outcomes Research, The Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA; Surgery Working Group, Society of Junior Doctors, Athens, Greece. Electronic address: dimitrisgiannhs@gmail.com.
• J. Clin. Virol. 2020 Jun 1; 127: 104362.

AbstractCoronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus strain disease, has recently emerged in China and rapidly spread worldwide. This novel strain is highly transmittable and severe disease has been reported in up to 16% of hospitalized cases. More than 600,000 cases have been confirmed and the number of deaths is constantly increasing. COVID-19 hospitalized patients, especially those suffering from severe respiratory or systemic manifestations, fall under the spectrum of the acutely ill medical population, which is at increased venous thromboembolism risk. Thrombotic complications seem to emerge as an important issue in patients infected with COVID-19. Preliminary reports on COVID-19 patients' clinical and laboratory findings include thrombocytopenia, elevated D-dimer, prolonged prothrombin time, and disseminated intravascular coagulation. As the pandemic is spreading and the whole picture is yet unknown, we highlight the importance of coagulation disorders in COVID-19 infected patients and review relevant data of previous coronavirus epidemics caused by the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV).Copyright © 2020 Elsevier B.V. All rights reserved.

30 keywords...

hide…